Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Cerebral Toxoplasmosis and AIDS (TOXODFA)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University Hospital, Limoges
ClinicalTrials.gov Identifier:
NCT00803621
First received: December 2, 2008
Last updated: March 22, 2014
Last verified: December 2013

December 2, 2008
March 22, 2014
June 2009
December 2012   (final data collection date for primary outcome measure)
Not Provided
To evaluate the diagnostic performance of the real-time PCR Toxoplasma assay from peripheral blood samples in cerebral toxoplasmosis in AIDS patients from the DFA. [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00803621 on ClinicalTrials.gov Archive Site
Isolation, genetic typing and storage of T. gondii strains collected among AIDS patients with cerebral toxoplasmosis from the DFA. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Isolation, genetic typing and storage of T. gondii strains collected among AIDS patients with cerebral toxoplasmosis from the DFA. [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Cerebral Toxoplasmosis and AIDS
Cerebral Toxoplasmosis and AIDS in the French Departments of America (DFA). Diagnostic Contribution of a PCR Assay and Genetic Diversity of Toxoplasma Gondii.

With a HIV incidence much higher in the DFA than in European French territory, this disease is a major public health problem in these areas, especially in French Guiana.

Cerebral toxoplasmosis is a priority among the opportunistic infections in AIDS patients from the DFA because of its frequency (French West Indies) and of its lethality (French Guiana).

The diagnosis of cerebral toxoplasmosis may be difficult because based only on presumptive clinical and radiological features. The response to specific antitoxoplasmic therapy confirms a posteriori the diagnosis.

In reference to the data collected by the Biological Resource Centre Toxoplasma, in particular in French Guiana, we think that T. gondii strains reactivating in AIDS patients from DFA are genetically different from those reactivating in AIDS patients from Europe, with an increased capacity for dissemination via peripheral blood in the first ones. This more frequent or more prolonged parasitemia could facilitate the diagnosis of cerebral toxoplasmosis by PCR test from peripheral blood samples in AIDS patients from the French departments of America.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

AIDS patients from the French West Indies and French Guiana having clinical and radiological suspicion of cerebral toxoplasmosis

  • Cerebral Toxoplasmosis
  • AIDS
Other: Toxoplasma PCR assay
Toxoplasma PCR assay
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
46
December 2013
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult patient (> 18 years)
  • Patient being informed and accepting to participate in the study with signature of informed consent
  • HIV positive serology
  • Clinical and radiological suspicion of cerebral toxoplasmosis justifying the start of specific antitoxoplasmic therapy

Exclusion Criteria:

  • Protected patient
  • Patient uncovered by social insurance
  • Specific antitoxoplasmic therapy already initiated since 72h or more
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT00803621
I07009
No
University Hospital, Limoges
University Hospital, Limoges
Not Provided
Study Director: Daniel AJZENBERG, PharmD, PhD CHU Limoges
University Hospital, Limoges
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP